fbpx

Isodiol Announces Stellar Revenue for May 2018

Isodiol International Inc. announced unaudited May 2018 consolidated revenues of $3,316,646 CDN.


CEO Marcos Agramont stated, “May was a historic month for revenues. These numbers legitimize what we have accomplished over the last several months, particularly with the acquisitions of Kure Corp and BSPG Laboratories Ltd.”


He added that shareholders can expect audited financials for the period of April 1, 2017 – March 31, 2018 to be available on July 30.


Moreover, the company officially opened new corporate headquarters in Vancouver. The new location will allow the team to focus on Canadian sales and expansion as cannabis laws continue to positively change within Canada.


In other news, two of Isodiol’s flagship medical products, Isoderm and Purodiol, were recently featured at the International League Against Epilepsy in Sao Paola, Brazil. The congress was hosted by neurology experts from around the world.


“As the company continues to expand its international footprint, it is crucial that we stay at the forefront of these conferences and educate the medical community about our approved deliveries of CBD and the recent approval of our API for use in finished pharmaceutical products,” said Mr. Agramont.


Isodiol continues to position itself as the go-to partner to supply cannabidiol (CBD) isolate of the highest quality. The management is actively working on its goal to enter international markets and increase revenue. The company foresees a bright future for CBD products due to increasing global demand.


About Isodiol International Inc.


Isodiol is a market leader in pharmaceutical-grade phytochemical compounds and an industry leader in the development of CBD consumer products.


It is one of the pioneers in the commercialization of 99%+ pure cannabinoids, microencapsulation, and nanotechnology.


The company manufactures the highest-quality consumable and topical products for skin care and pain management. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and the expansion of its phytoceutical portfolio.


Besides this, the company plans to aggressively expand into international markets like Latin America, Asia, and Europe.